Skip to main content
Premium Trial:

Request an Annual Quote

ViaLogy Expands Patent Portfolio into Biomarker Identification

NEW YORK, Jan. 6 (GenomeWeb News) - Active signal processing software firm ViaLogy said today that it has been issued a patent that extends its Quantum Resonance Interferometry (QRI) technology into the area of biomarker identification.

The patent, US No. 6,671,625, "Method and system for signal detection in arrayed instrumentation based on quantum resonance interferometry," covers the use of QRI in protein arrays, and "broadens applications of QRI to proteomics, pathway optimization, high-throughput screening, cellular assays and time-based dosing studies by gene expression," according to the company.

ViaLogy has already been issued three US patents -- numbers 6,245,511; 6,142,681; and 6,136,541 -- that cover the use of QRI for hybridized biochip and DNA microarray patterns, including diagnostic applications.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.